In a clinical trial, 21 patients with relapsed ovarian cancer received multiple intraperitoneal injections of MV-CEA within 4 weeks: 14 of them had stable disease (SD) after treatment, and five patients had decreased CA125 levels, which indicated that MV-CEA has good tumor-killing activity. The gene discussed is CEACAM5; the disease is ovarian cancer.